OT

OnKure Therapeutics, Inc.

OKUR·NASDAQ

$4.47

+8.5%
HealthcareBiotechnology

OnKure, Inc. engages in the discovery and development of oncology-precision medicines for the treatment of cancer. The company focuses on developing selective inhibitors of histone deacetylases. Its portfolio includes OKI-179, an inhibitor for the treatment of both hematological and solid tumors. The company was incorporated in 2011 and is based in Boulder, Colorado.

At a Glance

Live Snapshot
Market Cap$61.12M
EPS-4.4000
P/E Ratio-1.02
Earnings Date08/11/2026

okur

Net Debt

Last Annual Value

-58.50M

3-Year CAGR

-75%

5-Year CAGR

-20%

10-Year CAGR

-10%

OT

OnKure Therapeutics, Inc. Competitors Analysis of Net Debt

OKUR · NASDAQ
CompanyNet Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
-58.50M
N/AN/AN/A 
5.17B
N/AN/AN/A
-69.55M
N/AN/AN/A
-13.05M
N/AN/AN/A
6.88M
-9.9%N/A-3.8%
-130.58M
N/AN/AN/A
-71.33M
N/AN/AN/A
-79.15M
N/AN/AN/A
OT

OnKure Therapeutics, Inc. Fair Value Envelope

OKUR · NASDAQ

Our analysis suggests that OKUR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.47, this represents a potential HIDDEN relative to our calculated worth for OnKure Therapeutics, Inc..

Intrinsic Value
Current Price: $4.47